Discover the power of in-trial qualitative interviews in drug development and decision making.
In this free webinar we explore the value of these supplementary data to enhance clinical trial design, interpret findings and demonstrate value for payers while addressing unmet patient needs. You’ll gain a greater understanding of:
- The utilization of qualitative evidence in drug development
- How this evidence is valorized during evaluation by regulators and health technology assessment (HTA) bodies
- Implications for reimbursement decision-makers
Expert speakers from Evidera, part of the PPD clinical research business of Thermo Fisher Scientific, explore the added value of in-trial interview data in drug development and its pivotal role as a driver in decision making for regulatory and HTA decisions. The discussion will draw from case studies from multiple data sources, including FDA and EMA labels, HTA reports, and guidance documents.
SPEAKERS:
Carla Dias-Barbosa, MSc, Senior Research Leader & In-trial Research Lead, Patient-Centered Research, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
Miriam Kimel, PhD, Senior Research Scientist, Patient-Centered Research, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
Karen Bailey, PhD, Research Scientist, Patient-Centered Research, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
Paulina Rolska-Wójcik, PhD, Director, Value & Access Consulting, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific